Insider filing · XERS
John Johnson
Director
profile →
John Johnson sold $787K of Xeris Biopharma (XERS)
Executed Aug 13 2025, disclosed Aug 15 2025, 2 days later.
Value, as filed
$787K
107,500 sh × $7.32
Executed
Aug 13 2025
the trade date, as filed
Disclosed
Aug 15 2025
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
JJJohn Johnson (Director) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Axogen, Inc. (AXGN). The largest single filing was $1.4M of AXGN (45,379 sh across 4 lots, as filed), executed Dec 8 2025.
The name
XERS
Xeris Biopharma Holdings, Inc.
XERS · Healthcare · 32 filings in 24 months
ticker →
Healthcare · Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chron…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by John Johnson in XERS
XERSSALE
Xeris Biopharma Holdings, Inc.
$978K135,400 sh × $7.22
Exec Dec 19 2025
Filed Dec 19 2025 · 5:30 PM ET